8-K: Heron Therapeutics Secures $168M in Refinancing & Capital

Heron Therapeutics successfully refinanced existing debt and raised new capital through a series of agreements, including convertible notes, a private placement, and an expanded credit facility.

Summary

• Heron Therapeutics, Inc. (the "Company") completed a comprehensive refinancing and capital raise totaling approximately $168 million in gross proceeds and debt capacity.
• The Company entered into a Second Amendment to its Working Capital Facility Agreement with Hercules Capital, Inc., increasing the aggregate principal amount of term loans to up to $150,000,000, with $110,000,000 funded on the Closing Date.
• An Exchange Agreement was executed to exchange $150,000,000 aggregate principal amount of existing senior unsecured convertible promissory notes due 2026.
• Of the exchanged notes, $25,000,000 principal amount was exchanged for 16,666,666 shares of Common Stock, and the remaining $125,000,000 principal amount plus accrued interest was repaid in cash.
• A Note Purchase Agreement was signed for the issuance and sale of $35,000,000 aggregate principal amount of 5.0% convertible senior unsecured promissory notes due 2031 for an aggregate purchase price of $33,250,000.
• A Securities Purchase Agreement facilitated a private placement of 13,225,227 unregistered shares of Common Stock at $1.50 per share and 524,141 unregistered shares of Series A Convertible Preferred Stock (stated value $15.00 per share, convertible into 5,241,410 shares of Common Stock at $1.50 per share) for aggregate gross proceeds of approximately $27,700,000.
• The refinancing transactions closed on August 12, 2025.
• A Cooperation Agreement was entered into with Rubric Capital Management LP, increasing the Board of Directors' size from six to seven and appointing a Rubric-nominated director.
• The new convertible notes bear cash interest at 5.0% per year, with an option for the Company to pay interest in new notes at 7.0% per year until September 1, 2026.
• The conversion rate for the new convertible notes is initially 555.5556 shares of Common Stock per $1,000 principal amount, subject to adjustment.

Sentiment

Score: 8

Explanation: The filing indicates a significant and successful financial restructuring that addresses near-term debt maturities and provides substantial new capital. This improves the Company's financial stability and runway, which is a strong positive. However, the dilution from equity issuance and the ongoing financial covenants introduce some cautionary elements, preventing a perfect score.

Positives

• Successfully refinanced and extended the maturity of a significant portion of existing debt, improving the Company's liquidity profile.
• Secured substantial new capital through convertible notes ($33.25 million net) and a private placement ($27.7 million gross), providing additional working capital.
• Increased the working capital facility to $150 million, with $110 million immediately available, enhancing financial flexibility.
• The Cooperation Agreement with Rubric Capital Management LP, a significant investor, suggests improved alignment with shareholder interests and potentially stronger corporate governance.
• The exchange of $25 million of existing convertible notes into common stock reduces future cash interest obligations on that portion of debt.

Negatives

• The issuance of new convertible notes and common/preferred stock will result in dilution for existing shareholders.
• The new convertible notes carry a 5.0% cash interest rate, or 7.0% if paid in kind, adding to interest expense.
• The Hercules Capital facility includes prepayment charges (3.00% in year 1, 2.00% in year 2, 1.00% thereafter) and end-of-term charges (4.65% within 18 months, 5.40% within 36 months, 6.25% thereafter), which could be costly upon early repayment.
• The Company is subject to financial covenants under the Hercules facility, including minimum Qualified Cash, Net Product Revenue, and Adjusted EBITDA targets, which could restrict operational flexibility if not met.

Risks

• Beneficial ownership limitations (initially 19.99%) on the conversion of preferred stock and new convertible notes may restrict certain investors' ability to fully convert their holdings.
• Nasdaq conversion limits (30,658,359 shares) apply to the new convertible notes until stockholder approval is obtained, potentially limiting conversion flexibility.
• Failure to obtain stockholder approval for the conversion of preferred stock and new convertible notes could impact the Company's capital structure and future financing options.
• The Company is subject to Registration Delay Payments (up to 6% of the principal amount of notes) if it fails to timely file or maintain effectiveness of the registration statement for resale of shares.
• The Company must comply with various financial covenants under the Hercules loan, including maintaining minimum Qualified Cash ($27,500,000 before Tranche 3 milestone, $20,000,000 after), T6M Net Product Revenue ($85,000,000 by Sep 30, 2026, $100,000,000 by June 30, 2027), and T6M Adjusted EBITDA ($1.00 by Sep 30, 2026, $10,000,000 by June 30, 2027). Failure to meet these could trigger an Event of Default.
• The Company's ability to maintain its listing on The Nasdaq Capital Market is crucial, and non-compliance could lead to suspension or delisting.
• The Company is subject to various regulatory risks, including compliance with Healthcare Laws, Anti-Corruption Laws, and Sanctions, with potential for Material Adverse Effects from non-compliance or enforcement actions.
• Material Adverse Effect clauses in the loan documents are broad and could trigger events of default if the Company's business, operations, or financial condition significantly deteriorate.

Future Outlook

The Company's future outlook is focused on achieving specific financial milestones (Net Product Revenue and Adjusted EBITDA) to unlock additional tranches of the working capital facility and maintaining compliance with various financial and regulatory covenants. The Company also plans to seek stockholder approval for the conversion of Series A Convertible Preferred Stock and to register shares for resale, indicating a path towards greater liquidity for investors.

Management Comments

• Ira Duarte, Executive Vice President, Chief Financial Officer, signed the agreements on behalf of Heron Therapeutics, Inc.

Industry Context

This comprehensive refinancing and capital raise is typical for a biotechnology company like Heron Therapeutics, which often relies on external financing to fund research, development, and commercialization efforts. The mix of debt and equity, along with the restructuring of existing obligations, reflects a common strategy to manage cash flow and extend runway, especially for companies with commercialized products like ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. The involvement of a significant investor like Rubric Capital Management LP and the board seat indicates a strategic partnership aimed at long-term stability and growth.

Management Changes

Corporate Governance

Legal Proceedings

• The Company represents that there are no pending or threatened legal or governmental proceedings that would reasonably be expected to have a Material Adverse Effect.
• Events of Default under the Hercules Loan Agreement include fines, penalties, or final judgments aggregating in excess of $500,000 (not covered by insurance) that are not discharged or stayed within 10 days.
• Events of Default under the Note Purchase Agreement include final judgments for payment of money aggregating in excess of $10,000,000 that are not bonded, discharged, or stayed within 30 days.

Related Party Transactions

• Rubric Capital Management LP is a purchaser of the new convertible notes and acts as the Designated Agent for the Purchasers in the Note Purchase Agreement.
• Rubric Capital Management LP also entered into a Cooperation Agreement with the Company, leading to the appointment of a Rubric-nominated director to the Board of Directors.

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of common stock and convertible preferred stock, but benefit from improved financial stability and extended debt maturities. Increased investor representation on the board may also be seen as positive.
• Creditors: Existing convertible noteholders received a mix of cash and equity, while new convertible noteholders and Hercules Capital, Inc. became new or expanded creditors, benefiting from the Company's strengthened financial position.
• Employees/Management: The successful refinancing provides greater financial stability, which can support ongoing operations and strategic initiatives, potentially benefiting employees through continued employment and business growth.

Next Steps

• The Company will file a preliminary proxy statement within 30 calendar days after the Closing Date to seek stockholder approval for the issuance of all Conversion Shares.
• The Company will call and hold a Stockholder Meeting promptly after filing the proxy statement, but in any event prior to December 31, 2025, to obtain the Stockholder Approval Proposal.
• If Stockholder Approval is not obtained, the Company will hold additional Stockholder Meetings every 90 days thereafter until approval is secured.
• The Company will file a registration statement for the resale of the newly issued shares within 30 calendar days of the Closing Date and use commercially reasonable efforts to have it declared effective.
• The Company will enter into an agreement with the Designated Agent within 30 days after the Closing to preserve its net operating losses (NOLs) in accordance with Section 382 of the IRC.
• The Company may draw additional tranches of the Hercules loan (Tranche 2 and Tranche 3) upon achieving specific Net Product Revenue and Adjusted EBITDA milestones.

Key Dates

Recommendation

The Company has successfully executed a complex financial restructuring, addressing near-term debt maturities and securing significant new capital. This materially improves its liquidity and financial runway, which is a positive for stability. However, the transaction involves substantial dilution for existing shareholders and introduces new financial covenants and interest obligations. While the immediate financial risk is mitigated, the long-term value creation will depend on the Company's ability to meet its operational milestones, particularly revenue and EBITDA targets, and effectively utilize the new capital for growth. Given the mixed impact of dilution versus improved financial health, a 'hold' recommendation is appropriate as investors should monitor the Company's execution on its strategic and financial objectives.

Keywords

Heron Therapeutics, Refinancing, Convertible Notes, Private Placement, Debt Restructuring, Capital Raise, SEC Filing, Corporate Governance, Nasdaq, Biotechnology, Pharmaceuticals, Financial Covenants, Share Dilution